ABBV Jan 2024 115.000 put
| Previous close | 6.35 |
| Open | 6.35 |
| Bid | 6.25 |
| Ask | 8.05 |
| Strike | 115.00 |
| Expiry date | 2024-01-19 |
| Day's range | 6.35 - 6.35 |
| Contract range | N/A |
| Volume | |
| Open interest | 50 |
- Motley Fool
This Blockbuster Drug from AbbVie Is Closer to Another Major Indication
The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion that recommended the approval of AbbVie's (NYSE: ABBV) Rinvoq for what would be its fifth indication in that market. This would be to treat patients with moderate-to-severe ulcerative colitis who had an inadequate response to conventional therapies or biologic agents. A decision for Rinvoq as a treatment for moderate-to-severe ulcerative colitis patients from the European Commission is expected in the third quarter of this year.
- Motley Fool
3 Stocks You Can Buy and Hold for Decades
Three little words can make you a lot of money over the long term: Buy and hold. Here's why they picked AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Vertex Pharmaceuticals (NASDAQ: VRTX). Prosper Junior Bakiny (AbbVie): Pharma giant AbbVie is currently defying gravity.
- Motley Fool
Amgen's Beating the Market -- Here's Why It's a Buy Now
A blockbuster could be on the way next year -- but if you wait that long to invest, could it be too late?
